Instrument Inactif

Autres langues Ophthalix Inc Other OTC

Actions

US6837362010

Recherche biotechnologique et médicale

Autres langues

25/03/21	Wize Pharma : to change name to Mawson Infrastructure Group Inc
23/03/21	MAWSON INFRASTRUCTURE GROUP INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
11/03/21	Insider Trends: Wize Pharma Insider 90-Day Buying Trend Added to with Purchase
11/03/21	Insider Trends: Insider Purchase Adds to Wize Pharma Positive Trend
11/03/21	Insider Trends: Insider Buying Continued with Purchase of Wize Pharma Stock
10/03/21	WIZE PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
01/03/21	WIZE PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
21/02/21	Vertua Limited (NSX:VERA) Cosmos Investment Impact
16/02/21	WIZE PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
04/02/21	WIZE PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
19/01/21	WIZE PHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
05/01/21	WIZE PHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
04/01/21	Wize Pharma : Receives Bonus BioGroup Shares from Escrow and Additional Bonus BioGroup Shares Totaling $1.3 Million
31/12/20	WIZE PHARMA, INC. : Material Modification to Rights of Security Holders (form 8-K)
31/12/20	WIZE PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
30/12/20	Wize Pharma : and Cosmos Capital enter into Bid Implementation Agreement
09/12/20	WIZE PHARMA, INC. : Unregistered Sale of Equity Securities (form 8-K)
30/11/20	WIZE PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
16/11/20	WIZE PHARMA : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
12/11/20	Wize Pharma : Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome